JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 131 filers reported holding JOUNCE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 5.36 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $27,121 | -67.3% | 14,660 | -58.8% | 0.00% | – |
Q3 2022 | $83,000 | +22.1% | 35,599 | +58.2% | 0.00% | – |
Q2 2022 | $68,000 | -59.0% | 22,500 | -8.2% | 0.00% | -100.0% |
Q1 2022 | $166,000 | -19.0% | 24,500 | 0.0% | 0.00% | 0.0% |
Q4 2021 | $205,000 | +12.6% | 24,500 | 0.0% | 0.00% | -50.0% |
Q3 2021 | $182,000 | +9.0% | 24,500 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $167,000 | -24.4% | 24,500 | +14.0% | 0.00% | 0.0% |
Q1 2021 | $221,000 | +176.2% | 21,500 | +87.0% | 0.00% | +100.0% |
Q4 2020 | $80,000 | -19.2% | 11,500 | +4.5% | 0.00% | -50.0% |
Q3 2020 | $99,000 | +35.6% | 11,000 | 0.0% | 0.00% | +100.0% |
Q2 2020 | $73,000 | – | 11,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TRV GP II, LLC | 9,200,349 | $64,402,000 | 44.86% |
TRV GP III, LLC | 3,048,780 | $21,342,000 | 1.83% |
SILVERARC CAPITAL MANAGEMENT, LLC | 406,665 | $2,847,000 | 1.65% |
Sofinnova Investments, Inc. | 925,280 | $6,477,000 | 0.39% |
Omega Fund Management, LLC | 334,965 | $2,345,000 | 0.35% |
Yorktown Management & Research Co Inc | 49,200 | $344,000 | 0.31% |
Woodline Partners LP | 940,902 | $6,586,000 | 0.18% |
HUSSMAN STRATEGIC ADVISORS, INC. | 51,000 | $357,000 | 0.09% |
HORIZON FINANCIAL SERVICES, LLC | 12,005 | $84,000 | 0.08% |
Gyon Technologies Capital Management, LP | 26,893 | $188,000 | 0.06% |